SEARCH

SEARCH BY CITATION

References

  • Baer, M.R. (1998) Assessment of minimal residual disease in patients with acute leukemia. Current Opinion in Oncology, 10, 1722.
  • Beishuizen, A., Verhoeven, M.A., Van Wering, E.R., Hahlen, K., Hooijkaas, H., Van Dongen, J.J. (1994) Analysis of Ig and T-cell receptor genes in 40 childhood acute lymphoblastic leukemias at diagnosis and subsequent relapse: implications for the detection of minimal residual disease by polymerase chain reaction analysis. Blood, 83, 22382247.
  • Bendandi, M., Gocke, C.D., Kobrin, C.B., Benko, F.A., Sternas, L.A., Pennington, R., Watson, T.M., Reynolds, C.W., Gause, B.L., Duffey, P.L., Jaffe, E.S., Creekmore, S.P., Longo, D.L., Kwak, L.W. (1999) Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nature Medicine, 5, 11711177.DOI: 10.1038/13928
  • Bosch, G.J., Joosten, A.M., Kessler, J.H., Melief, C.J., Leeksma, O.C. (1996) Recognition of BCR-ABL positive leukemic blasts by human CD4+ T cells elicited by primary in vitro immunization with a BCR-ABL breakpoint peptide. Blood, 88, 35223527.
  • Campana, D. & Pui, C.H. (1995) Detection of minimal residual disease in acute leukemia: methodologic advances and clinical significance. Blood, 85, 14161434.
  • Cave, H., Guidal, C., Rohrlich, P., Delfau, M.H., Broyart, A., Lescoeur, B., Rahimy, C., Fenneteau, O., Monplaisir, N., D'Auriol, L., Elion, J., Vilmer, E., Grandchamp, B. (1994) Prospective monitoring and quantitation of residual blasts in childhood acute lymphoblastic leukemia by polymerase chain reaction study of delta and gamma T-cell receptor genes. Blood, 83, 18921902.
  • Cross, N.C., Feng, L., Chase, A., Bungey, J., Hughes, T.P., Goldman, J.M. (1993) Competitive polymerase chain reaction to estimate the number of BCR-ABL transcripts in chronic myeloid leukemia patients after bone marrow transplantation. Blood, 82, 19291936.
  • Drobyski, W.R. & Hessner, M.J. (1998) The use of the polymerase chain reaction to predict for subsequent relapse in unrelated marrow transplantation for chronic myelogenous leukemia. Leukemia and Lymphoma, 31, 317323.
  • Eder, M., Battmer, K., Kafert, S., Stucki, A., Ganser, A., Hertenstein, B. (1999) Monitoring of BCR-ABL expression using real-time RT-PCR in CML after bone marrow or peripheral blood stem cell transplantation. Leukemia, 13, 13831389.
  • Gerard, C.J., Olsson, K., Ramanathan, R., Reading, C., Hanania, E.G. (1998) Improved quantitation of minimal residual disease in multiple myeloma using real-time polymerase chain reaction and plasmid-DNA complementarity determining region III standards. Cancer Research, 58, 39573964.
  • Goulmy, E., Schipper, R., Pool, J., Blokland, E., Falkenburg, J.H., Vossen, J., Grathwohl, A., Vogelsang, G.B., Van Houwelingen, H.C., Van Rood, J.J. (1996) Mismatches of minor histocompatibility antigens between HLA-identical donors and recipients and the development of graft-versus-host disease after bone marrow transplantation. New England Journal of Medicine, 334, 281285.
  • Greenberg, P.D. (1991) Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells. Advances in Immunology, 49, 281355.
  • Heslop, H.E., Ng, C.Y., Li, C., Smith, C.A., Loftin, S.K., Krance, R.A., Brenner, M.K., Rooney, C.M. (1996) Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nature Medicine, 2, 551555.
  • Hsu, F.J., Caspar, C.B., Czerwinski, D., Kwak, L.W., Liles, T.M., Syrengelas, A., Taidi-Laskowski, B., Levy, R. (1997) Tumor-specific idiotype vaccines in the treatment of patients with B- cell lymphoma – long-term results of a clinical trial. Blood, 89, 31293135.
  • Ikeda, H., Lethe, B., Lehmann, F., Van Baren, N., Baurain, J.F., De Smet, C., Chambost, H., Vitale, M., Moretta, A., Boon, T., Coulie, P.G. (1997) Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor. Immunity, 6, 199208.
  • Inoue, K., Sugiyama, H., Ogawa, H., Nakagawa, M., Yamagami, T., Miwa, H., Kita, K., Hiraoka, A., Masaoka, T., Nasu, K., Kyo, T., Dohy, H., Nakauchi, H., Ishidate, T., Akiyama, T., Kishimoto, T. (1994) WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia. Blood, 84, 30713079.
  • Inoue, K., Ogawa, H., Yamagami, T., Soma, T., Tani, Y., Tatekawa, T., Oji, Y., Tamaki, H., Kyo, T., Dohy, H., Hiraoka, A., Masaoka, T., Kishimoto, T., Sugiyama, H. (1996) Long-term follow-up of minimal residual disease in leukemia patients by monitoring WT1 (Wilms tumor gene) expression levels. Blood, 88, 22672278.
  • Kwok, S. & Higuchi, R. (1989) Avoiding false positives with PCR. Nature, 339, 237238.
  • Lethe, B., Van Der Bruggen, P., Brasseur, F., Boon, T. (1997) MAGE-1 expression threshold for the lysis of melanoma cell lines by a specific cytotoxic T lymphocyte. Melanoma Research, 7, S83S88.
  • Lin, F., Van Rhee, F., Goldman, J.M., Cross, N.C. (1996) Kinetics of increasing BCR-ABL transcript numbers in chronic myeloid leukemia patients who relapse after bone marrow transplantation. Blood, 87, 44734478.
  • Lion, T., Gaiger, A., Henn, T., Horth, E., Haas, O.A., Geissler, K., Gadner, H. (1995) Use of quantitative polymerase chain reaction to monitor residual disease in chronic myelogenous leukemia during treatment with interferon. Leukemia, 9, 13531360.
  • Lowenberg, B., Downing, J.R., Burnett, A. (1999) Acute myeloid leukemia. New England Journal of Medicine, 341, 10511062.
  • Luthra, R., McBride, J.A., Cabanillas, F., Sarris, A. (1998) Novel 5′ exonuclease-based real-time PCR assay for the detection of t(14;18) (q32;q21) in patients with follicular lymphoma. American Journal of Pathology, 153, 6368.
  • Mannering, S.I., McKenzie, J.L., Fearnley, D.B., Hart, D.N. (1997) HLA-DR1-restricted bcr-abl (b3a2)-specific CD4+ T lymphocytes respond to dendritic cells pulsed with b3a2 peptide and antigen-presenting cells exposed to b3a2 containing cell lysates. Blood, 90, 290297.
  • Marchand, M., Van Baren, N., Weynants, P., Brichard, V., Dreno, B., Tessier, M.H., Rankin, E., Parmiani, G., Arienti, F., Humblet, Y., Bourlond, A., Vanwijck, R., Lienard, D., Beauduin, M., Dietrich, P.Y., Russo, V., Kerger, J., Masucci, G., Jager, E., De Greve, J., Atzpodien, J., Brasseur, F., Coulie, P.G., Van Der Bruggen, P., Boon, T. (1999) Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA- A1. International Journal of Cancer, 80, 219230.DOI: 10.1002/(sici)1097-0215(19990118)80:2<219::aid-ijc10>3.3.co;2-j
  • Marcucci, G., Livak, K.J., Bi, W., Strout, M.P., Bloomfield, C.D., Caligiuri, M.A. (1998) Detection of minimal residual disease in patients with AML1/ETO-associated acute myeloid leukemia using a novel quantitative reverse transcription polymerase chain reaction assay. Leukemia, 12, 14821489.
  • Massaia, M., Borrione, P., Battaglio, S., Mariani, S., Beggiato, E., Napoli, P., Voena, C., Bianchi, A., Coscia, M., Besostri, B., Peola, S., Stiefel, T., Even, J., Novero, D., Boccadoro, M., Pileri, A. (1999) Idiotype vaccination in human myeloma: generation of tumor-specific immune responses after high-dose chemotherapy. Blood, 94, 673683.
  • Mensink, E., Van De Locht, A., Schattenberg, A., Linders, E., Schaap, N., Geurts van Kessel, A., De Witte, T. (1998) Quantitation of minimal residual disease in Philadelphia chromosome positive chronic myeloid leukaemia patients using real-time quantitative RT-PCR. British Journal of Haematology, 102, 768774.DOI: 10.1046/j.1365-2141.1998.00823.x
  • Miller, Jr, W.H., Kakizuka, A., Frankel, S.R., Warrell, Jr, R.P., DeBlasio, A., Levine, K., Evans, R.M., Dmitrovsky, E. (1992) Reverse transcription polymerase chain reaction for the rearranged retinoic acid receptor alpha clarifies diagnosis and detects minimal residual disease in acute promyelocytic leukemia. Proceedings of the National Academy of Sciences of the United States of America, 89, 26942698.
  • Molldrem, J., Dermime, S., Parker, K., Jiang, Y.Z., Mavroudis, D., Hensel, N., Fukushima, P., Barrett, A.J. (1996) Targeted T-cell therapy for human leukemia: cytotoxic T lymphocytes specific for a peptide derived from proteinase 3 preferentially lyse human myeloid leukemia cells. Blood, 88, 24502457.
  • Moravcova, J., Lukasova, M., Stary, J., Haskovec, C. (1998) Simple competitive two-step RT-PCR assay to monitor minimal residual disease in CML patients after bone marrow transplantation. Leukemia, 12, 13031312.
  • Muto, A., Mori, S., Matsushita, H., Awaya, N., Ueno, H., Takayama, N., Okamoto, S., Kizaki, M., Ikeda, Y. (1996) Serial quantification of minimal residual disease of t(8;21) acute myelogenous leukaemia with RT-competitive PCR assay. British Journal of Haematology, 95, 8594.
  • Nestle, F.O., Alijagic, S., Gilliet, M., Sun, Y., Grabbe, S., Dummer, R., Burg, G., Schadendorf, D. (1998) Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nature Medicine, 4, 328332.
  • Neumann, E., Engelsberg, A., Decker, J., Storkel, S., Jaeger, E., Huber, C., Seliger, B. (1998) Heterogeneous expression of the tumor-associated antigens RAGE-1, PRAME, and glycoprotein 75 in human renal cell carcinoma: candidates for T-cell-based immunotherapies? Cancer Research, 58, 40904095.
  • Nieda, M., Nicol, A., Kikuchi, A., Kashiwase, K., Taylor, K., Suzuki, K., Tadokoro, K., Juji, T. (1998) Dendritic cells stimulate the expansion of bcr-abl specific CD8+ T cells with cytotoxic activity against leukemic cells from patients with chronic myeloid leukemia. Blood, 91, 977983.
  • Ohminami, H., Yasukawa, M., Fujita, S. (2000) HLA class I-restricted lysis of leukemia cells by a CD8 (+) cytotoxic T- lymphocyte clone specific for WT1 peptide. Blood, 95, 286293.
  • Pellat-Deceunynck, C., Mellerin, M.P., Labarriere, N., Jego, G., Moreau-Aubry, A., Harousseau, J.L., Jotereau, F., Bataille, R. (2000) The cancer germ-line genes MAGE-1, MAGE-3 and PRAME are commonly expressed by human myeloma cells. European Journal of Immunology, 30, 803809.DOI: 10.1002/(sici)1521-4141(200003)30:03<803::aid-immu803>3.0.co;2-e
  • Pongers-Willemse, M.J., Verhagen, O.J., Tibbe, G.J., Wijkhuijs, A.J., De Haas, V., Roovers, E., Van Der Schoot, C.E., Van Dongen, J.J. (1998) Real-time quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia using junctional region specific TaqMan probes. Leukemia, 12, 20062014.
  • Preudhomme, C., Henic, N., Cazin, B., Lai, J.L., Bertheas, M.F., Vanrumbeke, M., Lemoine, F., Jouet, J.P., Deconninck, E., Nelken, B., Cosson, A., Fenaux, P. (1997) Good correlation between RT-PCR analysis and relapse in Philadelphia (Ph1)-positive acute lymphoblastic leukemia (ALL). Leukemia, 11, 294298.
  • Radich, J., Gehly, G., Lee, A., Avery, R., Bryant, E., Edmands, S., Gooley, T., Kessler, P., Kirk, J., Ladne, P., Thomas, E.D., Appelbaum, F.R. (1997) Detection of bcr-abl transcripts in Philadelphia chromosome-positive acute lymphoblastic leukemia after marrow transplantation. Blood, 89, 26022609.
  • Reichardt, V.L., Okada, C.Y., Liso, A., Benike, C.J., Stockerl-Goldstein, K.E., Engleman, E.G., Blume, K.G., Levy, R. (1999) Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma – a feasibility study. Blood, 93, 24112419.
  • Roberts, W.M., Estrov, Z., Ouspenskaia, M.V., Johnston, D.A., McClain, K.L., Zipf, T.F. (1997) Measurement of residual leukemia during remission in childhood acute lymphoblastic leukemia. New England Journal of Medicine, 336, 317323.
  • Rosenberg, S.A., Yang, J.C., Schwartzentruber, D.J., Hwu, P., Marincola, F.M., Topalian, S.L., Restifo, N.P., Dudley, M.E., Schwarz, S.L., Spiess, P.J., Wunderlich, J.R., Parkhurst, M.R., Kawakami, Y., Seipp, C.A., Einhorn, J.H., White, D.E. (1998) Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nature Medicine, 4, 321327.
  • Seriu, T., Hansen-Hagge, T.E., Erz, D.H., Bartram, C.R. (1995) Improved detection of minimal residual leukemia through modifications of polymerase chain reaction analyses based on clonospecific T cell receptor junctions. Leukemia, 9, 316320.
  • Speck, B., Bortin, M.M., Champlin, R., Goldman, J.M., Herzig, R.H., McGlave, P.B., Messner, H.A., Weiner, R.S., Rimm, A.A. (1984) Allogeneic bone-marrow transplantation for chronic myelogenous leukaemia. Lancet, 1, 665668.
  • Tobal, K. & Yin, J.A. (1996) Monitoring of minimal residual disease by quantitative reverse transcriptase-polymerase chain reaction for AML1-MTG8 transcripts in AML-M2 with t(8;21). Blood, 88, 37043709.
  • Van Baren, N., Chambost, H., Ferrant, A., Michaux, L., Ikeda, H., Millard, I., Olive, D., Boon, T., Coulie, P.G. (1998) PRAME, a gene encoding an antigen recognized on a human melanoma by cytolytic T cells, is expressed in acute leukaemia cells. British Journal of Haematology, 102, 13761379.
  • Van Baren, N., Brasseur, F., Godelaine, D., Hames, G., Ferrant, A., Lehmann, F., Andre, M., Ravoet, C., Doyen, C., Spagnoli, G.C., Bakkus, M., Thielemans, K., Boon, T. (1999) Genes encoding tumor-specific antigens are expressed in human myeloma cells. Blood, 94, 11561164.
  • Warren, E.H., Greenberg, P.D., Riddell, S.R. (1998) Cytotoxic T-lymphocyte-defined human minor histocompatibility antigens with a restricted tissue distribution. Blood, 91, 21972207.
  • Watari, K., Tojo, A., Nagamura-Inoue, T., Nagamura, F., Takeshita, A., Fukushima, T., Motoji, T., Tani, K., Asano, S. (2000) Identification of a melanoma antigen, PRAME, as a BCR/ABL-inducible gene. FEBS Letters, 466, 367371.DOI: 10.1016/s0014-5793(00)01112-1
  • Yotnda, P., Firat, H., Garcia-Pons, F., Garcia, Z., Gourru, G., Vernant, J.P., Lemonnier, F.A., Leblond, V., Langlade-Demoyen, P. (1998) Cytotoxic T cell response against the chimeric p210 bcR-ABL protein in patients with chronic myelogenous leukemia. Journal of Clinical Investigation, 101, 22902296.